XML 41 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock, and Warrants With-Down Round Protection (Tables)
 12 Months Ended
Dec. 31, 2020
Schedule of Stock Grants Activity
Grants to Employees   Number     Weighted average exercise price (US$)  
Balance outstanding of December 31,2018     3,992,610       4.7  
Balance exercisable of December 31,2018     2,721,587     $ 4.63  
Granted during 2019     75,000     $ 4.5  
Forfeited during 2019     (2,039,525 )   $ 4.51  
Balance outstanding as of December 31,2019     2,028,085     $ 4.88  
Balance exercisable of December 31,2019     1,724,194     $ 4.63  
Granted during 2020     -     $ -  
Forfeited during 2020     (335,014 )   $ 4.51  
Balance outstanding as of December 31,2020     1,693,071     $ 4.95  
Balance exercisable of December 31,2020     1,667,853       4.96  
Schedule of Stock Grants, by Exercise Price Range

The following tables summarize information about options outstanding at December 31, 2020:

 

Exercise

price (US$)

     Outstanding at December 31, 2020     Exercisable at December 31, 2020     Weighted average remaining contractual life (years)  
                     
  4.50       1,298,859       1,273,651       6.54  
  6.25       344,212       344,212       1.19  
  7.75       50,000       50,000       6.26  
          1,693,071       1,667,863          
Schedule of Assumptions Used to Value Options

The following are the data and assumptions used:

 

Fair value calculations - Warrant   December 31, 2019  
Dividend yield (%)     -  
Expected volatility (%) (*)     56.32  
Risk free interest rate (%)     2.5  
Expected term of options (years)     5  
Exercise price (US dollars)     0.258-5.400  
Share price (US dollars) (**)     0.258  
Fair value (US dollars)     0.004-0.134  

 

    (*) Due to the low trading volume of the Company’s Common Stock, the expected volatility for 2019 grants was based on a sample of 248 companies operating in the Healthcare Products industry, respectively.
       
    (**) The Common Stock price, per share for the year ended December 31, 2019 reflects the Company’s management’s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2019, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series D Units.
Warrant [Member]  
Schedule of Fair Value Assumptions
    As of December 31, 2020, and 2019, the key inputs used in the fair value calculations of the warrant that were affected by the down-round protection were as follows:

 

Fair value calculations – Warrant   31-Dec-20     31-Dec-19  
Dividend yield (%)     -       -  
Expected volatility (%)     56.32       56.32  
Risk free interest rate (%)     2.5       2.5  
Expected term of options (years)     5       5  
Exercise price (US dollars)     0.4       0.258-5.400  
Share price (US dollars)     0.4       0.258  
Fair value (US dollars)     0.2       0.003-0.134